Strategic partnerships Mercodia is actively expanding its distribution network across Indonesia, Southeast Asia, Botswana, Namibia, South Africa, Uganda, and Zambia through multiple partner agreements, presenting a clear opportunity to engage regional distributors and identify co-selling and channel strategies.

On-demand offerings The launch of On-demand IAPP ELISA signals a move toward flexible, customer-centric assays. This creates upsell potential with clients seeking rapid, customizable biomarker solutions and could open doors for additional on-demand assay services or related biomarker panels.

Diversified bioanalysis Mercodia provides GLP-compliant bioanalytical CRO services from preclinical to clinical phases, focusing on diabetes, obesity, and cardiometabolic biomarkers. This positions them as a cross-functional partner for pharma/biotech programs needing reliable immunoassays across development stages.

Clinical diagnostics emphasis With core expertise in immunoassays for research and clinical diagnostics, there is potential to propose collaborations or SAAS-like service bundles around regulatory-compliant data generation, aiding sponsors aiming for biomarker-driven clinical endpoints.

Geographic expansion Recent partnerships and regional focus in Southeast Asia and Africa indicate growth momentum. A sales approach targeting regional biotechs, CROs, and academic centers in these markets could yield early access to demand for high-quality immunoassays and related services.